In the assessment of 12-month price targets, analysts unveil insights for Myriad Genetics, presenting an average target of ...

BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $9 from $11 and keeps an Underperform rating on the shares. Sentiment for ...

Fintel reports that on April 9, 2025, Guggenheim downgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Buy to ...

Myriad Genetics, Inc. MYGN reported fourth-quarter 2024 adjusted earnings of 3 cents per share, which came in line with the Zacks Consensus Estimate. The company reported earnings of 4 cents per ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

A month has gone by since the last earnings report for Myriad Genetics (MYGN). Shares have lost about 17.1% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Scotiabank analyst Sung Ji Nam maintained a Buy rating on Myriad Genetics (MYGN – Research Report) today and set a price target of $20.00. The ...

Shares of Myriad Genetics, Inc. (NASDAQ:MYGN – Get Free Report) have earned a consensus rating of “Hold” from the fifteen research firms that are currently covering the firm, Marketbeat reports. Three ...

Myriad Genetics (NASDAQ:MYGN – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Thursday.

BofA lowered the firm’s price target on Myriad Genetics (MYGN) to $9 from $11 and keeps an Underperform rating on the shares.Sentiment for Life Sciences and Diagnostic Tools and Contract ...